Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F M Muggia

Showing results (311-320 of 317) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 317 results.
The New England Journal of Medicine|December 3, 1987
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancerS D Williams, D M Stablein, L H Einhorn, et al.
Gynecologic Oncology|September 4, 2024
A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterusB Pothuri, Z Sawaged, H C Karpel, et al.
Journal of Liposome Research|February 27, 2003
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studiesJ Szebeni, L Baranyi, S Savay, et al.
Cancer Chemotherapy and Pharmacology|May 13, 1999
Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumorsR T Koda, A A Garcia, D J Chatterjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulationF M Muggia, J D Hainsworth, S Jeffers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycleA L Hamilton, J P Eder, A C Pavlick, et al.
Cancer Treatment Reports|July 1, 1976
Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lungJ H Edmonson, S W Lagakos, O S Selawry, et al.
Pageof 32

Showing results (311-320 of 317) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 317 results.
The New England Journal of Medicine|December 3, 1987
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancerS D Williams, D M Stablein, L H Einhorn, et al.
Gynecologic Oncology|September 4, 2024
A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterusB Pothuri, Z Sawaged, H C Karpel, et al.
Journal of Liposome Research|February 27, 2003
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studiesJ Szebeni, L Baranyi, S Savay, et al.
Cancer Chemotherapy and Pharmacology|May 13, 1999
Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumorsR T Koda, A A Garcia, D J Chatterjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulationF M Muggia, J D Hainsworth, S Jeffers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycleA L Hamilton, J P Eder, A C Pavlick, et al.
Cancer Treatment Reports|July 1, 1976
Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lungJ H Edmonson, S W Lagakos, O S Selawry, et al.
Pageof 32